{
  "source": "PA-Notification-Hycamtin.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1042-13\nProgram Prior Authorization/Notification\nMedication Hycamtin® (topotecan hydrochloride)\nDate Approved 1/12/2010, 9/2010, 12/2010, 7/2011, 8/2012, 2/2014, 2/2015, 2/2016,\n12/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021, 11/2022,\n11/2023, 11/2023\nDate Revised 2/1/2025\n1. Background:\nHycamtin (topotecan hydrochloride) is a topoisomerase inhibitor indicated for the treatment of\npatients with relapsed small cell lung cancer. The National Cancer Comprehensive Network\n(NCCN) also recommends Hycamtin may be considered as single-agent treatment (useful in\ncertain circumstances) for M1 disseminated disease with or without surgery and/or radiation\ntherapy if anti-PD-L1 or anti-PD-1 therapy is contraindicated or disease has progressed on anti-\nPD-L1 or anti-PD-1 therapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Hycamtin will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Small cell lung cancer (SCLC)\n1. Initial Authorization\na. Hycamtin will be approved based on all of the following criteria:\n(1) Diagnosis of small cell lung cancer (SCLC)\n-AND-\n(2) Patient has experienced a relapse of disease after initial first-line chemotherapy\n© 2024 UnitedHealthcare Services, Inc.\n1\n(e.g., cisplatin with etoposide)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Hycamtin will be approved based on the f",
    "t-line chemotherapy\n© 2024 UnitedHealthcare Services, Inc.\n1\n(e.g., cisplatin with etoposide)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Hycamtin will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Hycamtin\ntherapy\nAuthorization will be issued for 12 months.\nC. Merkel cell carcinoma\n1. Initial Authorization\na. Hycamtin will be approved based on all of the following criteria:\n(1) Diagnosis of Merkel cell carcinoma\n-AND-\n(2) Disease is M1 disseminated\n-AND-\n(3) Patient has a contraindication to or disease has progressed on anti-PD-L1 or\nanti-PD-1 therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Hycamtin will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Hycamtin\ntherapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Hycamtin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nSeptember 2018.\nThe NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/profes",
    ". Hycamtin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nSeptember 2018.\nThe NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed on\nOctober 11, 2024.\nProgram Prior Authorization/Notification - Hycamtin (topotecan hydrochloride)\nChange Control\n2/2014 Annual review. No change to coverage criteria.\n2/2015 Annual review. Added additional criteria to SCLC indication. Updated\nreferences.\n2/2016 Annual review. Changed all authorization to 12 months. Updated\nreferences.\n12/2016 Annual review. Updated references.\n11/2017 Annual review. Updated references.\n11/2018 Annual review. Added coverage for Merkel cell carcinoma based on\nNCCN guidelines. Updated background and references.\n11/2019 Annual review. Added NCCN recommended regimens criteria.\nUpdated references.\n11/2020 Annual review. Updated background to reflect package insert.\nUpdated SCLC criteria to reflect package insert. Updated references.\n11/2021 Annual review. Added clinical criteria for uterine neoplasms per\nNCCN recommendations. Updated reference.\n11/2022 Annual review. Removed criteria for uterine neoplasms since dosage\nform for treatment is IV. Added state mandate footnote. Updated\nreference.\n11/2023 Annual review. Updated Merkel cell carcinoma criteria based on\ncurrent NCCN recommendations. Updated background and reference.\n11/2024 Annual review with no changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}